Kapiloff Michael S, Emter Craig A
Cardiac Signal Transduction and Cellular Biology Laboratory, Interdisciplinary Stem Cell Institute, Departments of Pediatrics and Medicine, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA.
Department of Biomedical Sciences, University of Missouri-Columbia, Columbia, MO, USA.
F1000Res. 2016 Jan 18;5. doi: 10.12688/f1000research.7278.1. eCollection 2016.
The prevalence of heart failure is expected to increase almost 50% in the next 15 years because of aging of the general population, an increased frequency of comorbidities, and an improved survival following cardiac events. Conventional treatments for heart failure have remained largely static over the past 20 years, illustrating the pressing need for the discovery of novel therapeutic agents for this patient population. Given the heterogeneous nature of heart failure, it is important to specifically define the cellular mechanisms in the heart that drive the patient's symptoms, particularly when considering new treatment strategies. This report highlights the latest research efforts, as well as the possible pitfalls, in cardiac disease translational research and discusses future questions and considerations needed to advance the development of new heart failure therapies. In particular, we discuss cardiac remodeling and the translation of animal work to humans and how advancements in our understanding of these concepts relative to disease are central to new discoveries that can improve cardiovascular health.
由于总体人口老龄化、合并症发生率增加以及心脏事件后生存率提高，预计未来15年心力衰竭的患病率将增加近50%。在过去20年中，心力衰竭的传统治疗方法基本没有变化，这表明迫切需要为这一患者群体发现新的治疗药物。鉴于心力衰竭的异质性，明确心脏中导致患者症状的细胞机制非常重要，尤其是在考虑新的治疗策略时。本报告重点介绍了心脏病转化研究中的最新研究成果以及可能存在的陷阱，并讨论了推进新的心力衰竭治疗方法开发所需的未来问题和考虑因素。特别是，我们讨论了心脏重塑以及动物研究成果向人体的转化，以及我们对这些与疾病相关概念的理解进展如何对于能够改善心血管健康的新发现至关重要。
